(E/Z) -Droloxifene

• Description:

  (E/Z) -Droloxifene is a mixture of (E) -droloxifene (a selective estrogen receptor modulator) and (Z) -droloxifene. (E) -Droloxifene binds to the estrogen receptor (ER) with an IC50 value of 24 nM in rabbit uterine homogenates. (E) -Droloxifene increases uterine weight in immature rats, and reduces estradiol-induced increases in uterine weight in juvenile rats. (E) -Droloxifene also inhibits 17β-estradiol-stimulated growth of MCF-7, ZR-75-1, and T47D human breast cancer cells. (Z) -Droloxifene binds weakly to ER and has no estrogenic or antiestrogenic activity[1][2][3][4].

• Product Name Alternative:

  (E/Z) -3-Hydroxytamoxifen

• UNSPSC:

  12352005

• Target:

  Apoptosis; Estrogen Receptor/ERR

• Related Pathways:

  Apoptosis; Vitamin D Related/Nuclear Receptor

• Field of Research:

  Cancer

• Smiles:

  OC1=CC=CC(/C(C2=CC=C(C=C2)OCCN(C)C)=C(CC)/C3=CC=CC=C3)=C1

• Molecular Formula:

  C26H29NO2

• Molecular Weight:

  387.51

• References & Citations:

  [1]Robertson JF. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev. 2004 Dec;30 (8) :695-706.|[2]Kawamura I, et al. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers. Jpn J Pharmacol. 1993 Sep;63 (1) :27-34. |[3]Löser R, et al. Pharmacological activities of droloxifene isomers. Anticancer Res. 1988 Nov-Dec;8 (6) :1271-4.|[4]Hasmann M, et al. Preclinical data for Droloxifene. Cancer Lett. 1994 Sep 15;84 (2) :101-16.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [165813-01-4]